703 related articles for article (PubMed ID: 29606150)
1. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
2. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
4. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.
Chi A; Ma P; Fu G; Hobbs G; Welsh JS; Nguyen NP; Jang SY; Dai J; Jin J; Komaki R
PLoS One; 2013; 8(4):e59729. PubMed ID: 23577071
[TBL] [Abstract][Full Text] [Related]
5. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
6. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
[TBL] [Abstract][Full Text] [Related]
7. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases.
Chi A; Liao Z; Nguyen NP; Xu J; Welsh JS; Jang SY; Howe C; Komaki R
PLoS One; 2012; 7(4):e35809. PubMed ID: 22558228
[TBL] [Abstract][Full Text] [Related]
9. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
Hoffmann L; Persson GF; Nygård L; Nielsen TB; Borrisova S; Gaard-Petersen F; Josipovic M; Khalil AA; Kjeldsen R; Knap MM; Kristiansen C; Møller DS; Ottosson W; Sand H; Thing R; Pøhl M; Schytte T
Radiother Oncol; 2022 Jun; 171():53-61. PubMed ID: 35421513
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
11. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
Modh A; Rimner A; Williams E; Foster A; Shah M; Shi W; Zhang Z; Gelblum DY; Rosenzweig KE; Yorke ED; Jackson A; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1168-76. PubMed ID: 25303891
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases.
Chi A; Jang SY; Welsh JS; Nguyen NP; Ong E; Gobar L; Komaki R
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):856-62. PubMed ID: 21255942
[TBL] [Abstract][Full Text] [Related]
13. Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.
Zindler JD; Thomas CR; Hahn SM; Hoffmann AL; Troost EG; Lambin P
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26476075
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated protection : A new concept for high-precision radiation therapy.
Brunner TB; Nestle U; Adebahr S; Gkika E; Wiehle R; Baltas D; Grosu AL
Strahlenther Onkol; 2016 Dec; 192(12):886-894. PubMed ID: 27757502
[TBL] [Abstract][Full Text] [Related]
16. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
17. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Lu JY; Lin PX; Huang BT
Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
[TBL] [Abstract][Full Text] [Related]
18. 4π noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors.
Dong P; Lee P; Ruan D; Long T; Romeijn E; Low DA; Kupelian P; Abraham J; Yang Y; Sheng K
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):407-13. PubMed ID: 23523322
[TBL] [Abstract][Full Text] [Related]
19. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
20. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
